This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignee: Schering Corporation. Active years: 2007-2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2007-2010
Title: Inventor Thierry Oliver Fischmann: Pioneering Advances in ERK2 Polypeptide Crystallization
Introduction
Thierry Oliver Fischmann, a notable inventor based in Scotch Plains, NJ, has made significant contributions to the field of biochemistry through his groundbreaking work on ERK2 polypeptides. With two patents to his name, Fischmann is at the forefront of innovations that enhance drug design methodologies.
Latest Patents
Fischmann's latest patents focus on methods for crystallizing ERK2 polypeptides. The first patent details the creation of crystals of the ERK2 polypeptide and its complexes, which serve essential purposes in structure-assisted drug design. Similarly, his second patent reiterates the same focus on ERK2 crystals, emphasizing their utility in enabling more effective pharmaceutical developments. These innovations are pivotal for researchers and pharmaceutical companies aiming to design drugs with higher efficacy.
Career Highlights
Throughout his career, Fischmann has demonstrated a commitment to research and development. He works for Schering Corporation, a company that exemplifies innovation in the pharmaceutical industry. His role in advancing the understanding and application of ERK2 polypeptides positions him as a key contributor to the future of drug development.
Collaborations
Fischmann collaborates with talented professionals in the field, including Jessie M. English and Thomas E. Hesson. Their collaborative efforts enhance research output and innovation, fostering a productive environment where new ideas can thrive and transform into practical applications.
Conclusion
Thierry Oliver Fischmann is an inspiring figure in the realm of biochemistry and pharmaceutical innovation. His two patents for ERK2 polypeptide crystallization methods showcase his contributions to drug design and development. As he continues to work alongside reputable colleagues at Schering Corporation, Fischmann is sure to remain an influential inventor shaping the future of medical advancements.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile